Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527169) titled 'A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma' on April 7.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Metastatic Olfactory Neuroblastoma
Intervention:
Drug: Zanzalintinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: October 1, 2026
Target Sample Size: 16
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT...